← All Gilead Sciences, INC filings

Gilead Sciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
GILD
Gilead Sciences, INC
10-K: Gilead Reports Strong 2025 Growth, HIV Sales Up 6%
Gilead Sciences, Inc. reported a 2% increase in total revenues to $29.4 billion in 2025, driven by robust HIV product sales and significant R&D pipeline advancements, despite challenges in Veklury and Cell Therapy sales.
NASDAQ
GILD
Gilead Sciences, INC
10-K: Gilead Sciences Reports Mixed 2024 Results: HIV, Oncology Growth Offset by Veklury Decline and Impairment Charges
Gilead Sciences' 2024 results show revenue growth driven by HIV and oncology, but net income was significantly impacted by Trodelvy impairment charges and increased R&D expenses.
NASDAQ
GILD
Gilead Sciences, INC
10-K: Gilead Sciences Reports 2023 Financial Results, Highlights Pipeline Progress
Gilead Sciences' 2023 annual report reveals a slight revenue decrease offset by growth in HIV and oncology, alongside significant R&D investments and strategic collaborations.